Form 4: Corbus COO Sells Shares for Tax Obligations

Corbus Pharmaceuticals' Chief Operating Officer, Ian Hodgson, sold 2,415 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Ian Hodgson, Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc. (CRBP), reported a sale of common stock.
• The transaction involved the disposition of 2,415 shares of Common Stock, par value $0.0001 per share.
• The sale occurred on February 3, 2026, at a weighted average price of $8.0899 per share, with prices ranging from $8.01 to $8.15.
• The sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• This was a mandated sale by the Issuer and not a discretionary transaction by Mr. Hodgson.
• Following the reported transaction, Mr. Hodgson beneficially owns 51,927 shares, which includes 48,108 unvested RSUs subject to their respective vesting schedules.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary and solely for tax purposes, thus it does not reflect a change in management's confidence or the company's operational outlook.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing, as it primarily reports an insider transaction.

Management Comments

• The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ('RSUs').
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine mechanism for executives to satisfy tax liabilities upon the vesting of equity awards. Such transactions are generally not indicative of management's discretionary view on the company's future prospects or stock performance, distinguishing them from open market sales driven by investment decisions.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related event and is unlikely to have a significant direct impact on shareholder value or perception, as it does not signal a discretionary change in insider holdings.

Key Dates

Recommendation

The transaction is a non-discretionary 'sell to cover' for tax purposes related to RSU vesting. It does not provide new information regarding the company's fundamentals, strategic direction, or management's confidence in future performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Corbus Pharmaceuticals, CRBP, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Chief Operating Officer